Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

14. september 2026 opdateret af: InSilico Medicine Hong Kong Limited

A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.

The purpose of this study is to evaluate if Rentosertib (INS018_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018_055).

In this study, Rentosertib (INS018_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018_055) works to treat Idiopathic Pulmonary Fibrosis.

Studieoversigt

Status

Rekruttering

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

320

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Anhui
      • Hefei, Anhui, Kina
        • Ikke rekrutterer endnu
        • Anhui Provincial Hospital
      • Hefei, Anhui, Kina
        • Ikke rekrutterer endnu
        • Anhui Chest Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina
        • Rekruttering
        • Peking Union Medical College Hospital
      • Beijing, Beijing Municipality, Kina
        • Rekruttering
        • Beijing Friendship hospital, Capital Medical University
      • Beijing, Beijing Municipality, Kina
        • Ikke rekrutterer endnu
        • Beijing Chaoyang Hospital, Capital Medical University
    • Fujian
      • Fuzhou, Fujian, Kina
        • Ikke rekrutterer endnu
        • Fuzhou University Affiliated Provincial Hospital
      • Xiamen, Fujian, Kina
        • Rekruttering
        • The Second Affiliated Hospital of Xiamen Medical College
    • Guangdong
      • Guangzhou, Guangdong, Kina
        • Rekruttering
        • The First Affiliated Hospital of Guangzhou Medical University
      • Guangzhou, Guangdong, Kina
        • Ikke rekrutterer endnu
        • Nanfang Hospital, Southern Medical University
    • Guangxi
      • Nanning, Guangxi, Kina
        • Ikke rekrutterer endnu
        • The First Affiliated Hospital of Guangxi Medical University
    • Hainan
      • Haikou, Hainan, Kina
        • Rekruttering
        • Hainan General Hospital
    • Hebei
      • Shijiazhuang, Hebei, Kina
        • Ikke rekrutterer endnu
        • The Second Hospital of Hebei Medical University
      • Shijiazhuang, Hebei, Kina
        • Ikke rekrutterer endnu
        • Hebei Medical University Third Hospital
    • Henan
      • Anyang, Henan, Kina
        • Rekruttering
        • The People's Hospital of Anyang City
      • Nanyang, Henan, Kina
        • Rekruttering
        • Nanyang First People's Hospital
      • Zhengzhou, Henan, Kina
        • Ikke rekrutterer endnu
        • Henan Provincial People's Hospital
      • Zhengzhou, Henan, Kina
        • Ikke rekrutterer endnu
        • The First Affiliated Hospital of Zhengzhou University
    • Hubei
      • Wuhan, Hubei, Kina
        • Ikke rekrutterer endnu
        • Renmin Hospital of Wuhan University
      • Wuhan, Hubei, Kina
        • Ikke rekrutterer endnu
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Yichang, Hubei, Kina
        • Ikke rekrutterer endnu
        • Yichang Central People's Hospital
    • Hunan
      • Changsha, Hunan, Kina
        • Ikke rekrutterer endnu
        • The Second Xiangya Hospital of Central South University
      • Changsha, Hunan, Kina
        • Ikke rekrutterer endnu
        • The Xiangya Hospital of Central South University
    • Inner Mongolia
      • Hohhot, Inner Mongolia, Kina
        • Ikke rekrutterer endnu
        • The Affiliated Hospital of Inner Mongolia Medical University
    • Jiangsu
      • Nanjing, Jiangsu, Kina
        • Rekruttering
        • Nanjing Drum Tower Hospital
      • Xuzhou, Jiangsu, Kina
        • Ikke rekrutterer endnu
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, Kina
        • Ikke rekrutterer endnu
        • Jiangxi Provincial People' Hospital
    • Jilin
      • Changchun, Jilin, Kina
        • Ikke rekrutterer endnu
        • The Second Hospital of Jilin University
    • Liaoning
      • Shenyang, Liaoning, Kina
        • Ikke rekrutterer endnu
        • Shengjing Hospital of China Medical University
    • Shaanxi
      • Xi'an, Shaanxi, Kina
        • Rekruttering
        • The Second Affiliated Hospital of Xi'an Jiaotong University
      • Xi'an, Shaanxi, Kina
        • Rekruttering
        • The First Affiliated Hospital of Xi'an Medical College
    • Shandong
      • Jinan, Shandong, Kina
        • Ikke rekrutterer endnu
        • Qilu Hospital of Shandong University
      • Jinan, Shandong, Kina
        • Ikke rekrutterer endnu
        • Introduction of the First Affiliated Hospital of Shandong First Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina
        • Rekruttering
        • Shanghai Pulmonary Hospital Affiliated to Tongji University
    • Shanxi
      • Taiyuan, Shanxi, Kina
        • Ikke rekrutterer endnu
        • Shanxi Bethune Hospital
      • Yuncheng, Shanxi, Kina
        • Ikke rekrutterer endnu
        • Yuncheng Central Hospital
    • Sichuan
      • Chengdu, Sichuan, Kina
        • Ikke rekrutterer endnu
        • West China Hospital, Sichuan University
      • Chengdu, Sichuan, Kina
        • Ikke rekrutterer endnu
        • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina
        • Ikke rekrutterer endnu
        • Tianjin Medical University General Hospital
      • Tianjin, Tianjin Municipality, Kina
        • Ikke rekrutterer endnu
        • Tianjin Chest Hospital
    • Xinjiang
      • Ürümqi, Xinjiang, Kina
        • Ikke rekrutterer endnu
        • The First Affiliated Hospital of Xinjiang Medical University
    • Yunnan
      • Kunming, Yunnan, Kina
        • Ikke rekrutterer endnu
        • The First People Hospital of Yunnan Province
    • Zhejiang
      • Hangzhou, Zhejiang, Kina
        • Ikke rekrutterer endnu
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Hangzhou, Zhejiang, Kina
        • Rekruttering
        • Affiliated Hangzhou First People's Hospital,School of Medicine, Westlake University
      • Jiaxing, Zhejiang, Kina
        • Ikke rekrutterer endnu
        • The First Hospital of Jiaxing
      • Ningbo, Zhejiang, Kina
        • Ikke rekrutterer endnu
        • Ningbo Medical Center Lihuili Hospital
      • Ningbo, Zhejiang, Kina
        • Ikke rekrutterer endnu
        • The First Affiliated Hospital of Ningbo University
      • Wenzhou, Zhejiang, Kina
        • Ikke rekrutterer endnu
        • The First Affiliated Hospital of Wenzhou Medical University

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
  2. Patients aged ≥40 years at time of signing the ICF.
  3. Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
  4. UIP or probable UIP with fibrosis extent >10% at HRCT.
  5. Meet all the following criteria during the screening period:

    1. FVC ≥45% predicted of normal
    2. FEV1/FVC ≥0.7
    3. DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
  6. Background antifibrotic therapies are allowed, patients may be either:

    1. on a stable therapy with nintedanib or pirfenidone as monotherapy for at least 12 weeks prior to screening visit and during the screening period and are planning to stay on this background treatment after randomization.
    2. not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
  7. Estimated minimum life expectancy of at least 30 months for non-IPF related disease in the opinion of the investigator.
  8. Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.

Exclusion criteria:

  1. Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
  2. Previous participation in a clinical study with rentosertib (active or placebo).
  3. Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
  4. Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
  5. Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
  6. Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
  7. Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
  8. Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), hepatic steatosis (including non-alcoholic steatohepatitis and/or other types of fatty liver diseases).
  9. Patients with Gilbert's disease
  10. Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
  11. Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.5 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
  12. Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
  13. Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
  14. Patient with a history of lung volume reduction surgery or lung transplant.
  15. Current smoker and/or cotinine (smoking) test positive.
  16. History of drug abuse, drug use, or alcohol abuse within the past 3 months.
  17. Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
  18. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
  19. Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
  20. Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
  21. Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
  22. Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study

    1. Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
    2. Medications associated with substantial risk for prolongation of corrected QT interval.
  23. Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
  24. Patients who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study.
  25. Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
  26. Any condition that would interfere with the interpretation of study assessments or impair study participation.
  27. Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Active
Patients assigned will receive ISN018_055 tablets orally QD for 52 weeks
Dosage form: Tablets; Frequency of administration: Orally QD. Other Names: Rentosertib
Placebo komparator: Placebo
Patients assigned will receive matching placebo orally QD for 52 weeks
Dosage Form: Tablet; Frequency of administration: Oralt én gang dagligt.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks.
Tidsramme: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
time to first occurrence of any disease progression
Tidsramme: up to 52 weeks
including 1) percent predicted forced vital capacity decrease relative to baseline greater than 10%, 2) acute exacerbation of IPF, 3) respiratory-related hospitalization, or 4) death due to respiratory
up to 52 weeks
change from baseline to Week 52 in quantitative computed tomography-derived lung fibrosis burden on high-resolution computed tomography(HRCT)
Tidsramme: week 52
week 52
change from baseline in quality of life (QoL) as measured by the patient-reported outcomes questionnaires using King's Brief Interstitial Lung Disease questionnaire (K BILD)
Tidsramme: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52
change from baseline in QoL as measured by the patient-reported outcomes questionnaires using Living with Pulmonary Fibrosis(L-PF)
Tidsramme: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52
change from baseline in hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) over 52 weeks
Tidsramme: Weeks 0, 52
Weeks 0, 52

Andre resultatmål

Resultatmål
Tidsramme
Incidence of treatment-emergent adverse events(Safety and Tolerability), and clinically significant changes in physical examination,vital signs,safety laboratory test
Tidsramme: up to 56 weeks
up to 56 weeks
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG QTcF Interval
Tidsramme: Weeks 0,2,4,8,12,26,39,52
Weeks 0,2,4,8,12,26,39,52
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG Heart Rate
Tidsramme: Weeks 0,2,4,8,12,26,39,52
Weeks 0,2,4,8,12,26,39,52
changes from baseline in serum proteome by high throughput proteomic analysis at Weeks 12, 26, and 52
Tidsramme: weeks 0, 12 ,26, and 52
weeks 0, 12 ,26, and 52
changes from baseline in serum bone biomarker of procollagen 1 intact N-terminal propeptide [P1NP]
Tidsramme: weeks 0, 52
weeks 0, 52
changes from baseline in serum bone biomarker of C-terminal telopeptide [CTX]
Tidsramme: weeks 0, 52
weeks 0, 52

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

9. september 2026

Primær færdiggørelse (Anslået)

30. oktober 2029

Studieafslutning (Anslået)

30. oktober 2029

Datoer for studieregistrering

Først indsendt

22. juni 2026

Først indsendt, der opfyldte QC-kriterier

1. juli 2026

Først opslået (Faktiske)

7. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. september 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner